Candidate: Dr. Goff completed postgraduate training in 1985 and started the Schizophrenia Program of the Massachusetts General Hospital (MGH) with an NIMH """"""""Faculty Scholar Award in Schizophrenia"""""""" in 1988. He has focused on augmentation trials for negative symptoms, and over the past five years has conducted a series of studies examining glutamatergic agents and glutamatergic activity of atypical antipsychotics. Dr. Goff has also established a group of ten young investigators working collaboratively to translate recent advances in the neurosciences to the study and treatment of schizophrenia. Environment: Dr. Goo's group has ample space and access to schizophrenia subjects at the Freedom Trail Clinic of the Lindemann Mental Health Center and to a collaborative network of mental health clinics that he has established for recruitment of research subjects in the greater Boston area. He works closely with the MGH Neuroimaging group, the MGH Biostatistics Center, the MGH Amino Acid Laboratory and collaborates with the Transcranial Magnetic Stimulation Research Group at the Beth Israel Hospital and the Brain Imaging Center at McLean Hospital. Dr. Goff is principal investigator for the clinical trials section of the NIMH-funded Neurosciences Center for the Study of Glutamate in Schizophrenia under the leadership of Dr. Joseph Coyle. Dr. Goff has full institutional commitment from Dr. Jerrold Rosenbaum (interim Chief of Psychiatry, MGH) ensuring protected time and resources to accomplish research and mentoring goals. Research: Dr. Goo's research plan involves continuation of his study of glutamatergic agents in schizophrenia and of the role of glutamatergic activity in the therapeutic action of atypical antipsychotics. He will devote the period of the career development award to completing on-going RO1-funded controlled trials of NMDA receptor agonists, initiating trials of new glutamatergic agents (D-serine and an Ampakine) and developing expertise with new research tools and developing collaborations to apply to his research, including neuroimaging, spectroscopy, transcranial magnetic stimulation and genetics. He will also continue his mentoring activities as he guides the career development of ten junior faculty researchers in his group as well as residents and research fellows working on research projects under his direction.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24MH002025-03
Application #
6659719
Study Section
Special Emphasis Panel (ZMH1-ITV-D (01))
Program Officer
Hsiao, John
Project Start
2001-09-01
Project End
2006-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
3
Fiscal Year
2003
Total Cost
$137,638
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Cain, Christopher K; McCue, Margaret; Bello, Iruma et al. (2014) d-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr Res 153:177-83
Roffman, Joshua L; Brohawn, David G; Nitenson, Adam Z et al. (2013) Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull 39:330-8
Cather, Corinne; Dyer, Michael A; Burrell, Heather A et al. (2013) An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia. J Dual Diagn 9:87-93
Goff, Donald C (2012) D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull 38:936-41
Hermes, Eric; Nasrallah, Henry; Davis, Vicki et al. (2011) The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res 128:166-70
Buchanan, Robert W; Keefe, Richard S E; Lieberman, Jeffrey A et al. (2011) A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 69:442-9
Gottlieb, Jennifer D; Cather, Corinne; Shanahan, Meghan et al. (2011) D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res 131:69-74
Goff, Donald C; Hill, Michele; Barch, Deanna (2011) The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav 99:245-53
Roffman, Joshua L; Brohawn, David G; Friedman, Jesse S et al. (2011) MTHFR 677C>T effects on anterior cingulate structure and function during response monitoring in schizophrenia: a preliminary study. Brain Imaging Behav 5:65-75
Hill, Michele; Shannahan, Kelsey; Jasinski, Sarah et al. (2011) Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 127:41-5

Showing the most recent 10 out of 39 publications